Original Management Team Has Stepped Back in at Cytodyne with Plans for a Major Revival of the Xenadrine Brand in 2008

After a 5 year hiatus from the diet supplement industry, the original Cytodyne management team is back in the saddle and has announced plans for a major comeback of the Xenadrine line in 2008. First up for the much-lauded creators of Xenadrine RFA-1, the thermogenic that ushered in the modern era of thermogenic weight loss, is a high-performance replacement to the flagship product line, Ultra-Strength Xenadrine EFX.

Manasquan, NJ (PRWEB) January 16, 2008 -- Remember a time, several years ago, when it seemed like everyone you knew was losing weight with one specific, much-celebrated weight-loss formulation? Those were exciting days, filled with the promise of real and dramatic physical transformations. Now the company that launched that first golden age of thermogenic weight loss, Cytodyne Technologies (a division of NutraQuest Inc), and that brand, Xenadrine, have returned to the limelight with several official announcements that have rocked the diet supplement industry and inspired new hope in the hearts of fitness-conscious Americans everywhere.

First and foremost, Cytodyne Technologies has emerged from a self-imposed five-year hiatus from the retail marketplace. However, the team was certainly not resting during this time. To the contrary, they were devoting their time to working with top researchers on the intensive scientific investigation into new technologies designed to facilitate high-impact thermogenesis and weight loss. Those inquiries have yielded several innovative new weight-loss technologies and compounds, and Cytodyne is now poised to re-enter the diet supplement retail marketplace in a very high-profile way.

This is a thrilling time for us and for our many millions of loyal customers

Secondly, and perhaps even more importantly, Cytodyne is introducing a cutting-edge new version of its flagship Xenadrine-EFX product which will be called Ultra-Strength Xenadrine-EFX. This new version contains a unique patented compound that provides an added dimension of powerful weight-loss efficacy that goes beyond anything previously available in the EFX product line.

"This is a thrilling time for us and for our many millions of loyal customers," Cytodyne founder and president Bob Chinery says. "People thought we were gone, but the truth was the exact opposite. In fact, we were concentrating on research and development without the distractions of marketing and retailing. We assembled an elite research team headed by a renowned medical doctor and two leading university researchers and set them to work on a number of entirely new paths of scientific investigation regarding thermogenesis, fat loss, and energy production."

Cytodyne's five-year program of exclusive focus on research and development represents a radical departure from typical business protocol in the supplement industry. "Chinery has always been a fanatic about the hard science end of this business," says Cytodyne Director of Sales, Kelly Conklin. "I remember May of 2003, when he said we were going to license the brand to another company and focus exclusively on what we do best, developing innovative new products. I was shocked. We were far and away the #1 selling brand in the industry at that time. Any other company would have just coasted along and exploited the sales potential, but not Cytodyne. The standards for Chinery and his research team are so high that they wanted the ability to focus completely on the product development end of the business while others dealt with marketing and selling.    Chinery and his research team basically pioneered modern weight-loss supplementation with Xenadrine RFA-1 over a decade ago, and are now setting out to do the same thing a second time with this latest extended period of research, development, and testing. Now that I see how far ahead of the industry we are on the science end, it all makes sense. It would have been next to impossible to achieve these scientific developments while simultaneously managing the distractions of the sales and marketing end of the business.

"I look back at the last five years, and we probably lost plenty of potential revenue. On the other hand, with a solid bedrock of nearly five years' worth of cutting-edge research, data, and analysis by the top experts in the weight-loss field, plus some really exciting products on the verge of being released, it's clear that all the effort was worthwhile. With the innovations that have come out of this hard work, we are now poised to make up that lost ground and then some. But that's Chinery. He's all about innovation, quality control, and scientific integrity. So many companies in this business are about tomorrow's sales numbers, but Chinery has always emphasized the importance of extraordinary product quality as the foundation first and foremost. His philosophy has always been that if your product is truly outstanding, the sales will quickly follow."

Indeed, industry buzz has been building about the first of those products out of the pipeline, Ultra-Strength Xenadrine-EFX. Cytodyne has been keeping a tight rein on information about its newest product launch, but advance word on the newly patented weight-loss compound that functions as the cornerstone weight-loss agent in the new formulation has been overwhelmingly positive. And then there's the industry-wide whispering about an even more remarkable major thermogenic breakthrough on the horizon for later this year. No one associated with Cytodyne would provide any specifics, though Kelly Conklin was willing to admit, "That product is going to change the industry the way Xenadrine RFA-1 did in 1998."    

Meanwhile, competing manufacturers who have capitalized on Cytodyne's retailing pullback in recent years are understandably nervous. "Oh, yeah, they remember what happened last time," says Cytodyne Chief Scientific Advisor Jeff Volek. "Xenadrine RFA-1 dominated the industry. Everyone from elite athletes to housewives were using it and getting terrific weight-loss results. Xenadrine RFA-1 established benchmarks that other companies in this industry still haven't matched. It passed the strictest clinical tests universities and independent research facilities could subject it to. It even outperformed the prescription weight-loss drug Xenical® in a head-to-head clinical test. Now that the original Cytodyne team is back in the marketplace, these other companies may be looking at some lean years ahead."    

For right now, though, the original Cytodyne team is just happy to be back in a position where they can reach out to their devoted customers and return to the business of helping them achieve their fitness goals.

"At heart, we're research and development guys first and foremost," Chinery says. "But after five years of intense research and development, it's going to be fun to get out into the marketplace, introduce some products we're genuinely proud of, and go toe-to-toe with some of the hype-driven competition."

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SG9yci1Qcm9mLVRoaXItVGhpci1Mb3ZlLVplcm8=

cytodyne xenadrine xenadrine-efx weightloss xenadrine rfa weight loss supplements xenical dietary industry

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web